Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma
The addition of atezolizumab to EP did not improve PFS and OS in extrapulmonary NEC patients but did result in a higher response rate. Moreover, an NLR above 3 at diagnosis was identified as a poor prognostic factor for OS.
Authors
- Jiun‐I Lai (ORCID: https://orcid.org/0000-0002-8233-5466)
- I‐Wei Ho (ORCID: https://orcid.org/0009-0008-7503-0497)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Yi‐Ping Hung (ORCID: https://orcid.org/0000-0001-5221-6813)
- Nai‐Jung Chiang (ORCID: https://orcid.org/0000-0003-2743-9702)
- Peter Mu‐Hsin Chang (ORCID: https://orcid.org/0000-0003-1005-6545)
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming Chiao Tung University (TW)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1093/oncolo/oyae372
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taiwan Cancer Clinic Foundation
- Taipei Veterans General Hospital
- National Science and Technology Council